NGNE vs. PAHC, MLYS, COLL, SNDX, RCUS, ELVN, AVDL, SYRE, NTLA, and PHVS
Should you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Phibro Animal Health (PAHC), Mineralys Therapeutics (MLYS), Collegium Pharmaceutical (COLL), Syndax Pharmaceuticals (SNDX), Arcus Biosciences (RCUS), Enliven Therapeutics (ELVN), Avadel Pharmaceuticals (AVDL), Spyre Therapeutics (SYRE), Intellia Therapeutics (NTLA), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.
Neurogene vs.
Neurogene (NASDAQ:NGNE) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, community ranking, risk, analyst recommendations, media sentiment, earnings and profitability.
In the previous week, Neurogene had 14 more articles in the media than Phibro Animal Health. MarketBeat recorded 21 mentions for Neurogene and 7 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.16 beat Neurogene's score of 0.22 indicating that Phibro Animal Health is being referred to more favorably in the news media.
Neurogene presently has a consensus price target of $43.40, suggesting a potential upside of 141.25%. Phibro Animal Health has a consensus price target of $20.00, suggesting a potential downside of 16.67%. Given Neurogene's stronger consensus rating and higher probable upside, equities research analysts clearly believe Neurogene is more favorable than Phibro Animal Health.
Phibro Animal Health has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
52.4% of Neurogene shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 11.6% of Neurogene shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Phibro Animal Health has a net margin of 1.75% compared to Neurogene's net margin of 0.00%. Phibro Animal Health's return on equity of 25.35% beat Neurogene's return on equity.
Neurogene has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
Phibro Animal Health received 287 more outperform votes than Neurogene when rated by MarketBeat users. However, 90.91% of users gave Neurogene an outperform vote while only 59.81% of users gave Phibro Animal Health an outperform vote.
Summary
Phibro Animal Health beats Neurogene on 11 of the 18 factors compared between the two stocks.
Get Neurogene News Delivered to You Automatically
Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neurogene Competitors List
Related Companies and Tools
This page (NASDAQ:NGNE) was last updated on 5/19/2025 by MarketBeat.com Staff
